SLC5A2 and diabetes mellitus: With regard to glycemic therapies, the glucagon‐like peptide 1 receptor agonizts (GLP1‐RAs) and sodium‐glucose cotransporter 2 (SGLT2) inhibitors have both shown reductions in ASCVD events in patients with diabetes.36